Liaoning Cheng Da Co., Ltd. (SHA:600739)
9.80
-0.12 (-1.21%)
Oct 22, 2026, 3:00 PM CST
Liaoning Cheng Da Revenue
Liaoning Cheng Da had revenue of 2.42B CNY in the quarter ending June 30, 2026, a decrease of -8.39%. This brings the company's total for the last twelve months to 9.21B, down -12.12% year-over-year. In the year 2025, Liaoning Cheng Da had annual revenue of 9.90B, down -8.06%. That makes Liaoning Cheng Da the 6,276th largest company in the world by revenue and 859th in China.
Revenue (ttm)
9.21B
Revenue Growth
-12.12%
P/S Ratio
1.62
Revenue / Employee
3.36M
Employees
2,740
Market Cap
14.92B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Liaoning Cheng Da breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.90B | -868.14M | -8.06% |
| Dec 31, 2024 | 10.77B | -12.83M | -0.12% |
| Dec 31, 2023 | 10.78B | -3.78B | -25.97% |
| Dec 31, 2022 | 14.56B | -3.81B | -20.73% |
| Dec 31, 2021 | 18.37B | 1.43B | 8.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Pharmaceuticals Holding | 289.46B |
| Jointown Pharmaceutical Group | 167.56B |
| C.Q. Pharmaceutical Holding | 81.39B |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company | 77.91B |
| China National Accord Medicines Corporation | 72.89B |
| China National Medicines Corporation | 53.69B |
| China Meheco Group | 35.24B |
| Guangxi LiuYao Group | 21.15B |